Primary central nervous system lymphomas (PCNSL): MRI response criteria revised

W Küker; T Nägele; E Thiel; M Weller; U Herrlinger

doi:10.1212/01.wnl.0000178894.51436.54

Primary central nervous system lymphomas (PCNSL): MRI response criteria revised

Neurology. 2005 Oct 11;65(7):1129-31. doi: 10.1212/01.wnl.0000178894.51436.54.

Authors

W Küker¹, T Nägele, E Thiel, M Weller, U Herrlinger

Affiliation

¹ Department of Neuroradiology, Medical School, University of Tübingen, Berlin, Germany. wilhelm.kueker@orh.nhs.uk

PMID: 16217075
DOI: 10.1212/01.wnl.0000178894.51436.54

Abstract

The authors investigated the applicability of Macdonald response criteria to patients with primary CNS lymphoma (PCNSL). Four of 68 patients with persisting contrast-enhancing lesions after primary therapy did not receive further therapy, and none showed tumor progression after up to 54 months. Because contrast enhancement may not necessarily indicate residual, biologically active lymphoma, the authors propose a modification of the Macdonald response criteria.

Publication types

Multicenter Study

MeSH terms

Adult
Aged
Antineoplastic Agents / therapeutic use*
Central Nervous System Neoplasms / diagnosis*
Central Nervous System Neoplasms / drug therapy
Central Nervous System Neoplasms / physiopathology
Contrast Media
Disease Progression
Female
Humans
Lymphoma / diagnosis*
Lymphoma / drug therapy
Lymphoma / physiopathology
Magnetic Resonance Imaging / methods*
Magnetic Resonance Imaging / standards*
Male
Middle Aged
Neoplasm Recurrence, Local / diagnosis*
Neoplasm Recurrence, Local / drug therapy
Neoplasm Recurrence, Local / prevention & control
Predictive Value of Tests
Retrospective Studies
Treatment Outcome

Substances

Antineoplastic Agents
Contrast Media